Semaglutide is the active ingredient in Ozempic and Wegovy, and Medicare's coverage depends entirely on the approved use, not weight loss. Here is the 2026 reality.
Does Medicare cover semaglutide for weight loss?
No. Medicare Part D is prohibited by law from covering any drug used only for weight loss, and that includes semaglutide prescribed solely for that purpose. Semaglutide is sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and cardiovascular risk. A Part D plan may cover Ozempic for diabetes, or Wegovy to reduce the risk of cardiovascular death, heart attack, or stroke in adults with established cardiovascular disease who are overweight or obese, if the plan lists it. Call 1-800-MEDIGAP to see whether a covered path fits your diagnosis.
What are my covered options for semaglutide in 2026?
Coverage hinges on the approved indication. If you have type 2 diabetes, a plan may cover Ozempic or Rybelsus, often with prior authorization. If you have established cardiovascular disease and are overweight or obese, a plan may cover Wegovy for cardiovascular risk reduction. For obesity itself, semaglutide is not part of the 2026 GLP-1 Bridge, which covers Zepbound (tirzepatide). Because coverage depends on diagnosis and formulary, a free review at 1-800-MEDIGAP can identify which semaglutide or alternative GLP-1 your plan will actually cover, and at what cost.